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disease in Africa, Asia, and Latin America.
Soon these vaccines will undergo testing for
efficacy in one target group, young African
children. Trials of pre-erythrocytic vaccines de-
veloped by the Walter Reed Army Institute of
Research, USA, in collaboration with Glaxo-
SmithKline and the Oxford group (A. V. Hill
and collaborators), are now being tested for
safety and efficacy in Mozambique and East
Africa. Vaccines against blood stages of the
parasite will soon be tested for efficacy in Af-
rica by various groups. These initial studies will
give us a better measure of the challenge before
us. It is important to realize that, even if these
vaccine trials are successful, it will be 10 to 15
years before they have undergone sufficient
safety and efficacy trials to enable their broad
distribution to African children.
Drug resistance in P. falciparum blood stages
to the two most effective, inexpensive, and safe
antimalarials—chloroquine and Fansidar—has
driven the search for new drugs (9, 10). The
artemisinins, derived from the plant Artemisia
annua, are highly effective antimalarials that
have the added advantage that they reduce ga-
metocyte levels. Artemisinins combined with
Fansidar are being tested for efficacy and safety
in African children. Targets unique to Plasmo-
dium parasites—such as the hemoglobin diges-
tive vacuole and a plastid-like organelle called
the apicoplast—are attractive targets for new
antimalarial drugs. The recently described anion-
selective channel found only in the membranes
of parasite-infected red blood cells, which trans-
ports nutrients into erythrocytes (11), is also a
potential therapeutic target. Development of
drugs and vaccines is expensive and will require
large public-sector investment (12).
The main vectors of malaria in Africa, A.
gambiae and A. funestus, are extremely efficient
transmitters of this disease (i.e., they have high
vectorial capacity). One of the most important
variables in the formula devised by Macdonald
(13) to define vectorial capacity is the mosquito
life-span, an exponential term. If the mosquito
has a long life-span, then each human blood
meal (after parasite development in the blood)
can transmit the infection. Thus, average mos-
quito life-span is a major determinant of vecto-
rial capacity. For example, in Mopti, Mali, where
people may be bitten by 300 or more A. gambiae
per night, the malaria infection rate is extremely
low, largely because of the low survival of mos-
quitoes in this region. A low environmental tem-
perature (the temperature of the mosquito gut is
ambient temperature) results in a longer devel-
opment time for the parasite in the mosquito;
below 22°C, P. falciparum is unable to develop.
Thus, in mountainous areas of East Africa above
2000 m, there is little malaria transmission be-
cause it is too cold. Development of P. vivax in
the mosquito is less dependent on temperature,
so P. vivax transmission is found in some areas
(for example, the former Soviet Union) where
the average temperature is too low to allow P.
falciparum transmission. Another important
variable in determining the efficacy of a mosqui-
to as a malaria vector is the human biting rate,
because the mosquito must feed twice on hu-
mans: once to be infected and once to transmit
the disease.
Mosquitoes of the A. gambiae and A. fun-
estus population complex combine characteris-
tics of longevity and a preference for human
over animal blood. These vectors pose a huge
challenge, as evidenced by the malaria epidem-
ic that ensued when A. gambiae was acciden-
tally introduced into Brazil from Africa in 1930
by trading ships (14). A group of scientists
working on Aedes aegypti eradication to elim-
inate urban yellow fever identified A. gambiae,
and luckily they were able to eradicate this
intruder by treating water around dwellings
with larvicides. In Africa today, other vector
control approaches will be required. Informa-
tion from the Anopheles genome should make it
possible to genetically alter the characteristics
of A. gambiae and A. funestus that make them
such excellent vectors. For example, the vecto-
rial capacity of these mosquitoes could be re-
duced by decreasing their susceptibility to ma-
laria infection, decreasing their affinity for feed-
ing on humans, or decreasing their longevity.
Combining new antimalarials and vac-
cines with vector control measures will be
essential for halting transmission of malaria
in Africa and other endemic areas of the
world. The complete genome sequences of P.
falciparum and A. gambiae will be essential
to this endeavor.
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VIEWPOINT
A New Global Effort to Control Malaria
Jeffrey D. Sachs*
The time has come to resurrect a worldwide effort to control malaria,
following decades of neglect during which the disease has resurged in
many parts of sub-Saharan Africa and other endemic regions.
The global campaign to eradicate malaria,
launched in 1955 and phased out by the end
of the 1960s, has been dubbed a misguided
failure. Although the campaign did not come
close to achieving its headline objective of
eradicating malaria, it did lead to enormous
and sustained reductions in the burden of
malaria in dozens of countries around the
world. Unfortunately, the world failed to
heed the right lesson: Global eradication is
not feasible, but sustained malaria control
restricting transmission to low levels is.
The time has come to resurrect a worldwide
effort to control malaria, albeit one not
predicated on complete eradication of the
disease.
There are four reasons to launch a re-
newed global campaign against malaria.
First, the abandonment of control efforts has
led to a marked resurgence in disease and
deaths due to malaria in Africa and parts of
Asia, in part because of the spread of drug
resistance to first-line drugs and mosquito-
cides, and in part because of the generalized
collapse of public health services in Africa.
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particularly in sub-Saharan Africa where ma-
laria costs more than 1 million lives annually
and 1 percentage point of economic growth
per year (1). Second, substantial malaria con-
trol is possible by extending the coverage of
existing technologies to impoverished house-
holds and communities. Third, advances in
genomics including the completed genome
sequences of the mosquito Anopheles gam-
biae (2) and the malaria parasite Plasmodium
falciparum (3) offer promising new targets
for drug and vaccine development (4).
Fourth, many new programs to support a
global control effort have been established
recently, although a dire lack of funds pre-
vents them from operating effectively and at
a sufficiently broad scale.
Global control efforts from the 1940s to
the 1970s virtually eliminated malaria trans-
mission in the subtropics (Fig. 1). Malaria
became almost wholly a disease of the trop-
ics, particularly in Africa, where 90% of the
malaria deaths now occur. The reasons for
this are that the eradication campaign largely
bypassed Africa and that malaria in the sub-
tropics is easier to control because the inten-
sity of transmission is much lower (5, 6).
Still, successes in the sub-tropics and various
sites in tropical regions (7, 8) demonstrated
that intensive vector control measures com-
bined with stepped-up coverage of medical
treatment of infected individuals could bring
transmission down sharply, and in some set-
tings completely.1
The eradication effort was abandoned
when it became apparent that eradication was
not possible. Resistance to DDT, the corner-
stone of indoor residual spraying, appeared in
mosquito vector species; meanwhile, the ma-
laria parasite was becoming resistant to chlo-
roquine and other first-line drugs. Yet, even
when cases of malaria rebounded dramatical-
ly in some places (such as Sri Lanka) because
of DDT resistance, malaria death rates rarely
reverted to earlier levels. And even with DDT
resistance, the pesticide still proved effective
in limiting transmission (9). In short, the
eradication effort made real and sustained
strides, and much more could have been ac-
complished. A deeper reason for abandoning
the campaign may have been geopolitical.
Malaria control had already been achieved in
the southern United States, southern Europe,
southern regions of the Soviet Union, much
of Latin America, and large parts of Asia,
especially China. Moreover, by the mid-
1970s, the United States had withdrawn from
Vietnam, so that the U.S. military evinced a
sharply reduced concern for malaria control.
Impoverished Africans were not on the geo-
political radar screen.
The end of the global malaria eradication
campaign coincided with a general downturn
in foreign aid. Africa fell into a significant
debt crisis in the early 1980s, from which it
has not yet recovered. Creditor governments
and international institutions such as the In-
ternational Monetary Fund and World Bank
pushed for budget cuts in poor countries to
make room for foreign debt servicing. Public
health spending collapsed throughout Africa
and with it the limited malaria control efforts
that were in place. Spending cuts coincided
with three other adverse trends in Africa, and
parts of India, Southeast Asia and Latin
America: (i) population growth that pushed
human settlements into new ecological re-
gions supporting malaria transmission; (ii)
the growth of a “septic fringe” around Afri-
ca’s sprawling urban settlements where urban
transmission could thrive; and (iii) the con-
tinuing spread of drug and pesticide resis-
tance.
Donor fatalism also took hold in the shad-
ow of the “failed” eradication efforts. The
World Bank made only two loans in the
1990s specifically designated as malaria-con-
trol loans, to India and Laos, and not a single
loan to sub-Saharan Africa (10). Research
programs of the U.S. military and U.S. Agen-
cy for International Development directed at
a malaria vaccine or new drug development
were cut back. The major pharmaceutical
companies neglected malaria drug discovery
or vaccine research because the travelers’
market (visitors from the United States and
Europe to malarious regions) was small and
still handled by existing medicines.
By the late 1990s, much of the African
political leadership had become desperate, and
made a renewed malaria control campaign a
pivotal demand during the election of the
World Health Organization (WHO) director-
general in 1998. Roll Back Malaria (RBM) was
launched by a consortium of the WHO, World
Bank, United Nations Development Program,
and United Nations Children’s Fund in Novem-
ber 1998. Other initiatives for drug discovery,
vaccine development, and increased financing
of control efforts were launched, including the
research-oriented Multilateral Initiative on
Malaria (MIM, in 1997), Medicines for Ma-
laria Venture (MMV, in 1999), and the Ma-
laria Vaccine Initiative (MVI, in 1999). The
Global Fund to Fight AIDS, TB, and Malaria
(GFATM, launched in January 2002) sup-
ports the implementation of prevention and
treatment programs. All remain woefully un-
derfunded, and an effective international ef-
fort has not yet begun.
An effective campaign will need to oper-
ate on four principles. First, it should focus
on the most afflicted regions, mainly sub-
Saharan Africa. Second, it should recognize
that among the major epidemic diseases, ma-
laria control is uniquely site specific, depen-
dent on climate patterns, vector ecology and
biology, and human activity. Third, the cam-
paign should pursue two tracks: increased
malaria control (both prevention and treat-
ment) with existing technologies, together
with a major investment in R&D for new
technologies. Fourth, and above all, it should
be funded adequately and consistently for at
least two to three decades if it is to have a
chance of success. Current worldwide donor
spending for prevention and treatment pro-
grams is $100 to $200 million per year (and it
is symptomatic of the laxity of global control
efforts that up-to-date worldwide data have
not been compiled). Actual needs exceed $2
billion dollars per year, and probably more, to
fund replacements for chloroquine and other
drugs to which resistance has developed (11).
Promising new drugs already available
but not yet in widespread use include the
artemisinin-based compounds, developed in
the 1970s by Chinese scientists from deriva-
Earth Institute, Columbia University, New York, NY
10027, USA.
*The author is chairman of the WHO Commission on
Macroeconomics and Health and Special Advisor to
UN Secretary GeneralKoﬁ Annan.
Fig. 1. The shrinking range of malaria is depicted by overlaying WHO maps for malaria risk for the
years 1946 (pink), 1966 (red), and 1994 (brown). [Reproduced from (15)]
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Qinghaosu. Donors have been reluctant to sup-
port the introduction of artemisinin into Africa,
both because of its high unit cost relative to
chloroquine and other first-line drugs—chloro-
quine costs 10 cents for a curative regimen
whereas artemisinin costs $1—and out of fear
that artemisinin too will rapidly generate resis-
tance. To counteract this risk, artemisinin-based
compounds should be introduced in combina-
tion with other antimalarial drugs. Ironically,
the delay in sponsoring such an approach is
leading to the indiscriminate spread of artemisi-
nin-based monotherapies through informal drug
supply networks in Africa.
Encouragingly, in regions of Africa contain-
ing intensive economic activity (mines, oil
fields, rubber plantations, urban zones, tourist
sites), corporate malaria control efforts bol-
stered by public support are making a big dif-
ference (12). Successful corporate efforts gen-
erally rely on an intensive mix of environmental
vector-control measures, individual protection
of workers through household residual spray-
ing, and case management. Recent initiatives
by the world economic forum and other busi-
ness groups plan to link these corporate efforts
to broader international malaria control pro-
grams, particularly through formal public-pri-
vate partnerships (13).
Longer term, more sweeping solutions will
come from new drug discovery and especially
vaccine-development efforts based on recent
genomic advances. No major pharmaceutical
company reports a concerted malaria research
effort. The Gates Foundation has valiantly
aimed to spearhead new research by supporting
the drug-development MMV and the MVI.
MMV has the declared goal of developing one
new antimalarial drug every 5 years at a cost of
$150 million, or $30 million per year, plus
significant “in-kind” industry support. These
numbers are below most estimates of drug-
development costs, and are very unlikely to
cover the high expenses of drug trials. A rea-
sonable estimate of total worldwide public and
private annual spending on malaria drug and
vaccine research is less than $100 million, or
less than one-seventh of 1% of the $70 billion
or more of annual worldwide biomedical R&D,
for a disease that accounts for about 3% of the
worldwide disease burden as measured by dis-
ability-adjusted life years (14). R&D donor
needs for drugs and vaccines are around $1
billion per year on a sustained basis, compared
with current annual spending of less than $150
million.
The RBM consortium, headquartered at
WHO, should serve as the nerve center of a
renewed global effort to fight malaria. This
consortium should immediately prepare a
comprehensive strategy that includes an op-
erational multiyear plan of action together
with a full assessment of donor funding
needs. The proposed budget should clearly
delineate the separate needs for current pre-
vention and treatment programs, largely
funded through the GFATM and the World
Bank; the rapid development, clinical testing,
and procurement of artemisinin-based and
other drug combinations; and the outlays for
R&D for new drug discovery and vaccine
development, including effective systems for
high-cost clinical trials. Annual outlays by
donors must reach several billion dollars per
year for a generation or so to get malaria
under control in endemic areas of Africa and
Southeast Asia. But this will be a very small
price to pay for millions of lives saved per
year and for hundreds of millions of people to
be given the chance to escape from the vi-
cious cycle of poverty and disease.
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VIEWPOINT
Plasmodium Chloroquine Resistance and the
Search for a Replacement Antimalarial Drug
Thomas E. Wellems
Genetic and biochemical research is providing new information on the
mechanism of chloroquine resistance. Drug discovery initiatives are ﬁnd-
ing new leads that have favorable pharmaceutical properties and efﬁcacy
against chloroquine-resistant malaria.
The discovery of chloroquine and its subse-
quent worldwide use against malaria in the 20th
century produced one of the greatest public
health advances ever achieved by a drug against
an infectious disease. Chloroquine’s efficacy,
affordability, easy administration, and low tox-
icity led to marked reductions in morbidity and
mortality across the Americas, Africa, Asia,
and Oceania. Chloroquine remained effective
for decades. Despite its distribution in massive
quantities (including distribution in the salt sup-
plies of some countries), many years passed
before chloroquine resistance (CQR) began to
spread. Plasmodium falciparum, the most ma-
lignant of the four human malaria parasite spe-
cies, showed foci of CQR in Southeast Asia and
South America in the late 1950s, Papua New
Guinea in the 1960s, and East Africa in the late
1970s. The steady and unremitting spread of
CQR from these foci could only be met by a
few alternative drugs, all of which were more
expensive, encountered resistance problems of
their own, or were less safe and more difficult
to use than chloroquine itself. Morbidity and
mortality from P. falciparum malaria conse-
quently resurged, especially among children in
Africa (1). Malaria caused by Plasmodium
vivax, second only to P. falciparum malaria in
its impact on health and economic develop-
ment, remained responsive to chloroquine ev-
erywhere until a little over a decade ago, when
Laboratory of Malaria and Vector Research, National
Institute of Allergy and Infectious Diseases, Bethesda,
MD 20892, USA. E-mail: tew@helix.nih.gov
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